Efficacy and safety of once-weekly bortezomib in multiple

Efficacy and safety of once-weekly bortezomib in multiple
myeloma patients
by Sara Bringhen, Alessandra Larocca, Davide Rossi, Maide Cavalli, Mariella
Genuardi, Roberto Ria, Silvia Gentili, Francesca Patriarca, Chiara Nozzoli, Anna
Levi, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Vincenzo Rizzo,
Clotilde Cangialosi, Pellegrino Musto, Luca De Rosa, Anna Marina Liberati, Mariella
Grasso, Antonietta P. Falcone, Andrea Evangelista, Michele Cavo, Gianluca
Gaidano, Mario Boccadoro, and Antonio Palumbo
Blood
Volume 116(23):4745-4753
December 2, 2010
©2010 by American Society of Hematology
Kaplan-Meier survival curves for patients who received once-weekly (gray line) or twice-weekly
(black line) bortezomib (intention-to-treat population).
Sara Bringhen et al. Blood 2010;116:4745-4753
©2010 by American Society of Hematology
Cumulative incidence of sensory PN, accounting for competing events (death and any other PN
type) in patients who received once-weekly or twice-weekly bortezomib.
Sara Bringhen et al. Blood 2010;116:4745-4753
©2010 by American Society of Hematology